No profile data available.
LB Pharmaceuticals Inc (LBRX) is a healthcare company in the brain and nerve treatment drugs industry, based in New York, United States, with about 49 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$25.21 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $1.20 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases.
LB Pharmaceuticals reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$1.20 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Taysha Gene Therapies, Inc. (TSHA), Mind Medicine (MindMed) Inc. (MNMD), GH Research PLC (GHRS), Capricor Therapeutics, Inc. (CAPR).